Mosaiques’ diagnostics study entitled:

“CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer”

was awarded in 13. Nordkongress Urologie in Hamburg

13 – 15 June 2019

The study presents a CE-MS based urinary test of 19-peptides that enables detection of significant prostate cancer in patients with low levels of PSA (<15ng/ml) with sensitivity of 90% (AUC=0.81), outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69)

Please find more information on the Study:
https://www.ncbi.nlm.nih.gov/pubmed/31092909

Read more here:

http://www.nordkongress2019.de/?s=Home